Our passion in quality and innovation
moves us forward
HOW WE MAKE A DIFFERENCE
At Atilar Pharma, our mission is to provide the highest quality compounded medications to healthcare providers. With Benito Aguilar at the helm, we bring decades of industry expertise and a commitment to excellence to the 503B industries.
We believe that quality and cleanliness should never be compromised. That’s why we have taken extra steps to ensure that our facilities exceed the strict standards set by the FDA for 503B Outsourcing Facilities. From our state-of-the-art equipment to our rigorous quality protocols, we are dedicated to delivering the safest and most effective compounded medications possible.
Our team of experts is constantly monitoring our processes and making improvements to stay ahead of the curve. We understand the importance of providing safe and effective treatments to patients, and we’re committed to doing so with the utmost care and attention to detail.
We believe that everyone deserves access to the best possible healthcare, and we are proud to be a part of making that a reality. We are here to make a positive difference in the world.
10% OFF
Submit your Letter of Intent (LOI)
between December 1, 2023 and April 30, 2024,
and receive 10% off on all orders
for one year
5% OFF
Submit your Letter of Intent (LOI)
between May 1 and May 31, 2024,
and receive 5% off on all orders
for one year
Secure your discount
by pre-ordering today
A BRIEF HISTORY
Section 503B of the Federal Food and Drug Administration Act was created as a result of no oversight and substandard compounding practices at the New England Compounding Center. The tragic consequence was a severe outbreak of fungal meningitis.
Although the practice of pharmacy compounding had been around for decades, it was suddenly thrust into the national spotlight. Subsequently, the enactment of the DQSA in 2013 authorized the FDA, under Sections 503A and 503B, to create two types of compounding entities: 503A compounding pharmacies, and 503B outsourcing facilities.
Current Good Manufacturing Practices provide numerous mechanisms for manufacturers to supply drug products that are pure, safe, and effective. These procedures also equip FDA inspectors with guidelines and regulations regarding the issuance of observations, warning letters, and injunctions.
OUR CORE VALUES
At Atilar Pharma, we pride ourselves on upholding a set of core values that guide our decisions and actions every day. Our commitment to these values is at the heart of everything we do and helps us to fulfill our mission
ATTITUDE
We strive to maintain a positive, can-do attitude in everything we do, from providing exceptional customer service to creating high-quality, innovative products.
TEAM
We place a high value on teamwork. We believe that by collaborating and supporting each other, we can achieve more than we ever could alone.
INTEGRITY
We hold ourselves to the highest ethical standards in everything we do, from our manufacturing processes to our interactions with our customers and partners.
LIFE
We understand the critical role our products play in the lives of patients, and we are committed to ensuring the highest quality and safety standards in all our manufacturing processes.
ACCOUNTABLE
We take our responsibilities very seriously. We hold ourselves accountable for our actions and decisions and are always looking for ways to improve and do better.
RESPECT
We believe that respect is the foundation of any successful business relationship. That’s why we treat our employees, customers, and partners with the utmost respect, valuing their input and working together to achieve shared goals.
LATEST NEWS
Atilar Pharma has announced the launch of its high-quality compounded medications. With a focus on patient safety and quality, the company aims to revolutionize the 503B industry with its innovative…
Atilar Pharma, a leading 503B outsourcing facility providing high-quality compounded medications, and ESC Environmental Systems Corporation, a global leader in providing turnkey environmental and cleanroom solutions, have announced a strategic…